Chicago Equity Partners’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Chicago Equity Partners’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-6,915	Closed	-$539K	–	976
2019 Q3	$539K	Sell	6,915 -7,680	-53%	-$721K	0.03%	666
2019 Q2	$1.5M	Sell	14,595 -4,475	-23%	-$348K	0.07%	410
2019 Q1	$1.4M	Sell	19,070 -170	-0.9%	-$11.6K	0.05%	425
2018 Q4	$816K	Sell	19,240 -285	-1%	-$11.4K	0.03%	526
2018 Q3	$920K	Sell	19,525 -11,725	-38%	-$653K	0.03%	540
2018 Q2	$1.54M	Buy	+31,250	New	+$1.18M	0.05%	436

Other funds holding MRTX

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Chicago Equity Partners's MRTX Position: Q4 2019 in Review

Chicago Equity Partners sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2019, closing a stake of 6,915 shares — an estimated $539K sold.

Chicago Equity Partners first reported a position in MRTX in Q2 2018 and held it in 6 quarters. The position peaked at $1.54M in Q2 2018. 190 funds tracked by Wall St. Rank hold MRTX as of Q4 2019.

Chicago Equity Partners reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
Chicago Equity Partners sold 6,915 Mirati Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $539K.
Chicago Equity Partners first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2018 and held it in 6 quarters.
Chicago Equity Partners's Mirati Therapeutics, Inc. Common Stock position peaked at $1.54M in Q2 2018.
190 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2019.

Based on Chicago Equity Partners's 13F filing for Q4 2019, filed 10 Feb 2020.